Company Overview

Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems for underserved neurological, psychiatric, and pain-related conditions. The company operates within the biotechnology and specialty pharmaceutical industries, with research programs involving ketamine-based therapies, psychedelic-derived compounds, and targeted central nervous system (CNS) applications. Its primary business model centers on advancing intellectual property, licensing agreements, sponsored research partnerships, and preclinical or early-stage clinical development programs.

The company has historically emphasized collaborations with academic institutions and contract research organizations to support formulation development and translational research. Silo Pharma’s positioning has been tied to emerging interest in psychedelic-assisted therapeutics and intranasal or controlled-release drug delivery technologies. Public filings and company disclosures indicate that its strategy evolved from broader biotechnology licensing activity into a more concentrated CNS and psychedelic therapeutics focus, particularly following increased industry investment in neuropsychiatric treatment innovation.

Business Operations

Silo Pharma generates activity primarily through research and development initiatives rather than commercial product sales. Its operations have included therapeutic candidates targeting post-traumatic stress disorder (PTSD), stress-induced psychiatric disorders, fibromyalgia, chronic pain conditions, and neurodegenerative applications. Programs disclosed in public filings have included collaborations involving ketamine formulations and other CNS-focused compounds, with work conducted through third-party laboratories, university relationships, and external development partners.

The company’s operations are primarily based in the United States, though aspects of research, intellectual property development, and manufacturing support may involve international service providers and research contractors. Public disclosures have referenced relationships with academic and research institutions, including work associated with licensed technologies and sponsored studies. Data regarding large-scale international commercial operations or material revenue-generating subsidiaries remains limited based on available public sources.

Strategic Position & Investments

Silo Pharma’s strategic direction has centered on advancing differentiated CNS therapeutics through licensing arrangements, intellectual property expansion, and formulation technologies designed to improve drug delivery and patient outcomes. The company has publicly emphasized development pathways involving intranasal administration systems and controlled-release mechanisms intended to address limitations associated with conventional psychiatric and pain treatments. Its growth strategy has relied heavily on capital markets financing, research partnerships, and progression of preclinical assets toward regulatory milestones.

The company has also pursued portfolio expansion through intellectual property agreements and collaborative development arrangements rather than large-scale acquisitions. Publicly disclosed initiatives have included programs associated with PTSD treatment candidates and biomarker-driven neurological research. Compared with larger pharmaceutical competitors, Silo Pharma operates as a small-cap biotechnology issuer with a focused pipeline strategy rather than diversified commercial operations. Information regarding material subsidiary holdings or major acquisition activity is limited in public filings, and some program-specific development timelines remain subject to regulatory and financing conditions.

Geographic Footprint

Silo Pharma is headquartered in the United States and primarily conducts its corporate and research oversight activities domestically. Its operational footprint appears concentrated in North America, particularly through relationships with U.S.-based research institutions, laboratories, and development partners. Public disclosures do not indicate substantial direct commercial infrastructure across multiple continents.

The company’s broader market relevance is tied more to participation in the global biotechnology and psychedelic therapeutics sectors than to extensive physical international operations. Research collaborations, intellectual property activities, and outsourced development services may involve international counterparties, but publicly available information does not demonstrate a major multinational operating presence comparable to larger pharmaceutical companies.

Leadership & Governance

Silo Pharma is led by executives with backgrounds in biotechnology commercialization, capital markets, and pharmaceutical development. The company’s governance structure reflects a typical small-cap biotechnology model, with management focused on licensing strategy, research advancement, and investor financing activities. Public communications and regulatory filings have consistently emphasized disciplined pipeline advancement, intellectual property protection, and strategic collaborations as central elements of management’s operating philosophy.

Key executives identified in public filings include:

• Eric Weisblum – Chief Executive Officer
• James Kuo, M.D. – Chairman of the Board
• David Michery – Director

Data regarding broader executive leadership composition, including certain operational or financial leadership roles, is inconclusive based on available public sources and may change frequently due to the company’s size and developmental-stage structure.